Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 EUR | -1.74% | +1.20% | +31.01% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.01% | 128M | - | ||
+46.03% | 55.66B | B- | ||
-7.53% | 38.98B | B | ||
+36.02% | 38.8B | A | ||
-9.38% | 27.32B | C | ||
+12.31% | 26.29B | B- | ||
-16.38% | 20.25B | B | ||
+30.79% | 12.76B | B+ | ||
+28.57% | 12.18B | C+ | ||
-0.36% | 12.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ATYR Stock
- 471A Stock
- Ratings aTyr Pharma, Inc.